Novartis Gene Therapies
2275 Half Day Road, Suite 200
About Novartis Gene Therapies
Since 2013, Novartis Gene Therapies (formerly AveXis) has had one focus: bringing change to those devastated by genetic diseases.
The Novartis Gene Therapies culture embraces this mission. As a compassionate and dedicated team, we are enthusiastic about the science behind our work and finding answers to difficult questions. We are dedicated to communities affected by rare diseases, and these patients and families are the motivation for everything we do.
We have built a team with exceptional depth of experience, unified by a common vision; to develop gene therapies with the potential to positively impact the lives of the patients and families devastated by rare and life-threatening neurological genetic diseases. Though we are proud of what we have achieved to date, we remain relentlessly focused on making that vision a reality.
With cutting-edge technology, we are making progress in the treatment of rare and life-threatening neurological genetic diseases. Our initial gene therapy for spinal muscular atrophy (SMA) has been approved in the U.S., Japan, EU and Brazil.
We are headquartered in Bannockburn, IL with another location in Deerfield, IL. Our manufacturing facilities are located in Libertyville, IL, Durham, NC and Longmont, CO. Our research site is located in San Diego, CA. The European headquarters is located in Zurich, Switzerland and Novartis Pharma K.K. (“Novartis Pharma”) is located in Tokyo, Japan.
Stock Symbol: NVS
Stock Exchange: NYSE
101 articles with Novartis Gene Therapies
The Novartis Institutes for BioMedical Research (NIBR) is ending its early-stage anti-infectives research programs located in Emeryville, California. As a result, the company expects to lay off about 140 employees.
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
Switzerland-based Novartis announced it plans to spin off Alcon, its eye care division, into a separately-traded standalone company.
A new report highlights some concerns about the long-term commercial viability of game-changing gene therapies that can radically transform the lives of patients.
PTC Therapeutics presented updated interim clinical data from Part 1 of its FIREFISH clinical trial of risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy.
6/12/2018Regenxbio snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier this year.
REGENXBIO Receives $100 Million Accelerated License Payment Due to Acquisition of AveXis by Novartis
REGENXBIO Inc. announced that it has received an accelerated license payment of $100 million under its license agreement (the License Agreement) with AveXis, Inc.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Shares of Novartis are down nearly 3 percent this morning after the company reported a sharp decline in generic drugs and sales results from key branded medicines that missed analysts’ projections for the first quarter.
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
The net proceeds to AveXis from the offering, after deducting the underwriting discounts and commissions and other offering expenses payable by AveXis, are estimated to be approximately $431.9 million.
The offering is expected to close on or about January 19, 2018, subject to customary closing conditions.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Additionally, the company announced the first patient has been dosed in the Phase 1 trial of AVXS-101 in SMA Type 2.
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
AveXis’ initial proprietary gene therapy candidate, AVXS-101, is in a pivotal trial for the treatment of SMA Type 1, and a Phase 1 trial for SMA Type 2. AVXS-101 uses REGENXBIO’s NAV AAV9 vector.
AveXis Announces Alignment With FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1
The goal of the end-of-Phase 1 meeting was to review the non-clinical, clinical and Chemistry, Manufacturing and Controls data that has been generated by AveXis to date.
AveXis Announces Plan to Initiate Phase I Trial in SMA Type II Utilizing Intrathecal Delivery of AVXS-101
The company plans to initiate this trial immediately.